InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Lubniewski John L, Chairman & CEO. Insider active across 1 companies, notably HTG Molecular Diagnostics, INC. Aggregated, 13 disclosures have been recorded. The latest transaction was filed on 30 June 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
€6061 shares@ €0.9830.4% of flow
Common Stock
SEC:0001209191-22-040338:0·
€4481,000 shares@ €0.44823.0% of flow
Common Stock
SEC:0001209191-22-036957:0·
€7862 shares@ €1.25540.5% of flow
Common Stock
SEC:0001209191-22-022364:0·
€29762 shares@ €4.78594.1% of flow
Common Stock
SEC:0001209191-22-000830·
€29762 shares@ €4.78592.0% of flow
Common Stock
SEC:0001209191-22-000830:0·
€3,1541,000 shares@ €3.153643.3% of flow
Common Stock
SEC:0001209191-21-069771·
€3,1541,000 shares@ €3.153620.8% of flow
Common Stock
SEC:0001209191-21-069771:0·
€30662 shares@ €4.93334.2% of flow
Common Stock
SEC:0001209191-21-059000·
€30662 shares@ €4.93332.0% of flow
Common Stock
SEC:0001209191-21-059000:0·
€30462 shares@ €4.90024.2% of flow
Common Stock
SEC:0001209191-21-045179·
€30462 shares@ €4.90022.0% of flow
Common Stock
SEC:0001209191-21-045179:0·
€3,2191,000 shares@ €3.219144.2% of flow
Common Stock
SEC:0001209191-21-040442·
€3,2191,000 shares@ €3.219121.3% of flow
Common Stock
SEC:0001209191-21-040442:0·
13 of 13 declarations
About Lubniewski John L
John L. Lubniewski is the President and CEO of HTG MOLECULAR DIAGNOSTICS, INC. He leads the company by implementing strategies aimed at improving performance and fostering innovation in the molecular diagnostics sector.
